Fulltext

Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae

Harris PN 1 , Yin M 2 , Jureen R 3 , Chew J 4 , Ali J 5 , Paynter S 6 Show all authors , Paterson DL 7 , Tambyah PA 2

Affiliations 

  • 1 University of Queensland Centre for Clinical Research, Brisbane, Queensland Australia ; Department of Infectious Diseases, National University Hospital, Singapore, Singapore ; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
  • 2 Department of Infectious Diseases, National University Hospital, Singapore, Singapore ; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
  • 3 Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore ; Department of Laboratory Medicine, National University Hospital, Singapore, Singapore
  • 4 International Medical University, Kuala Lumpur, Malaysia
  • 5 Department of Infectious Diseases, National University Hospital, Singapore, Singapore
  • 6 School of Population Health, University of Queensland, Brisbane, QLD Australia
  • 7 University of Queensland Centre for Clinical Research, Brisbane, Queensland Australia
Antimicrob Resist Infect Control, 2015;4:14.
PMID: 25932324 DOI: 10.1186/s13756-015-0055-6

Abstract

Extended-spectrum β-lactamase (ESBL) producing Enterobacteriaceae are often susceptible in vitro to β-lactam/β-lactamase inhibitor (BLBLI) combination antibiotics, but their use has been limited by concerns of clinical inefficacy. We aimed to compare outcomes between patients treated with BLBLIs and carbapenems for bloodstream infection (BSI) caused by cefotaxime non-susceptible (likely ESBL- or AmpC β-lactamase-producing) Escherichia coli and Klebsiella pneumoniae.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications